Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Damage-control phosphatase 1 (DCPH1, ARMT1) is a metal-dependent enzyme implicated in maintaining cellular integrity by controlling the accumulation of damaged metabolites, especially fructose phosphates with glycation potential[1][3][7]. Structurally, it belongs to the DUF89 protein family and features a conserved α-β-α core fold with catalytic activity requiring divalent cations such as Co²⁺, Ni²⁺, Mn²⁺, or Mg²⁺[1]. DCPH1 demonstrates phosphatase activity towards multiple substrates, with highest activity against fructose-1-phosphate, a potent glycating agent linked to DNA damage[1][3]. It has also been shown to mediate O-methyltransferase reactions that modify glutamate residues in proteins and may participate in DNA damage response by methylating targets such as PCNA[3]. No direct drug interactions are known, and while disease relevance is suggested by its role in damage control and possible links to anemia and cancer, clinical validation as a drug target or biomarker is lacking[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Damage-control phosphatase 1 (DCPH1).